Athinoula A. Martinos Center for Biomedical Imaging

TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138

Retrieved on: 
Monday, July 31, 2023
Molecular biology, Real-time, Human, Therapy, Anatomy, Clinical trial, Radiology, Cancer, Transcoding, Physiology, Massachusetts General Hospital, Drug metabolism, RNA, Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Biomedicine, Patient, DMPK, Hospital, NHP, Pharmaceutical industry, Medical imaging, Pharmacokinetics

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates (NHPs), showing that the therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution.

Key Points: 
  • BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates (NHPs), showing that the therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution.
  • In addition, the pharmacodynamic activity of radiolabeled TTX-MC138 following a microdose injection was determined by measuring inhibition of the therapeutic target, miRNA-10b, using qRT-PCR.
  • Importantly, even at a microdose, the therapeutic showed lasting activity and significantly inhibited its target, miRNA-10b, known to be a driver of metastatic progression in a number of cancers.
  • TransCode is enrolling patients in a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers ( https://clinicaltrials.gov/study/NCT05908773?spons=transcode&rank=1 ).

TransCode Therapeutics to present at AACR Annual Meeting 2023

Retrieved on: 
Thursday, April 6, 2023
Abstract (summary), Surgical oncology, AACR, Therapy, Senior, Cancer research, Cancer, Transcoding, Massachusetts General Hospital, Targeted therapy, Research, Medical imaging, Conference proceedings, RNA, Trial of the century, Harvard Medical School, Gastrointestinal tract, Athinoula A. Martinos Center for Biomedical Imaging, Animal, Patient, Division, Hospital, FDA, Henri, Pharmaceutical industry

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19.

Key Points: 
  • BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19.
  • The study represents a collaboration between TransCode Therapeutics and the Athinoula A. Martinos Center for Biomedical Imaging and the Division of Gastrointestinal and Oncologic Surgery at the Massachusetts General Hospital and Harvard Medical School.
  • Testing of the Company’s lead therapeutic candidate, TTX-MC138, in preclinical models of pancreatic adenocarcinoma demonstrating efficacy, pharmacodynamic activity, and mechanism of action.
  • “The scope of research presented by TransCode at this year’s AACR Meeting attests to the rapid progress the Company is making toward its objective of bringing all its therapeutic candidates to cancer patients,” stated Zdravka Medarova, CTO and Co-Founder of TransCode Therapeutics.

The Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital selects Cubresa’s BrainPET Insert System to support brain research studies

Retrieved on: 
Monday, January 23, 2023
Technology, Health Technology, Neurology, Other Science, Mental Health, Research, Medical Devices, Healthcare Reform, Public Policy, Government, Hospitals, Other Professional Services, Biotechnology, AIDS, Professional Services, Health, General Health, Science, Other Manufacturing, Other Technology, Hardware, Manufacturing, Data Management, Biometrics, Other Health, Brain, Integration, Acquisition, PET, HIV/AIDS, Depression, Schizophrenia, Harvard Medical School, Bipolar disorder, Medical imaging, DSM-IV codes, Spectrum, Associate, Athinoula A. Martinos Center for Biomedical Imaging, Anxiety, Mental health, Radiology

The Martinos Center has selected Cubresa’s investigational BrainPET System to add to their suite of imaging tools.

Key Points: 
  • The Martinos Center has selected Cubresa’s investigational BrainPET System to add to their suite of imaging tools.
  • “We expect this unique MR-compatible head-only PET insert to advance a range of ongoing studies of neurological disorders, for example, while fostering opportunities for new projects and collaborations.”
    “Dr.
  • Catana and his colleagues are world leaders in integrated PET/MRI research”, said Dr. James Schellenberg, Cubresa’s Founder and CEO.
  • “We are extremely pleased to have them join our Foundational Client Program and have Cubresa’s BrainPET support their vast brain research activities.

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

Retrieved on: 
Wednesday, November 9, 2022
Risk, Department, Human body weight, Massachusetts General Hospital, Therapy, PD-L1, Company, Security (finance), Recurrence, Pancreatic cancer, Tumor microenvironment, Animation, Immunotherapy, Center, Drug discovery, Biomedicine, RNA, Hospital, Athinoula A. Martinos Center for Biomedical Imaging, U.S. Securities and Exchange Commission, Breast, Cancer, Neoplasm, Transcoding, CEO, Glioblastoma, COVID-19, RNA transfection, Private Securities Litigation Reform Act, MOA, PDAC, Nasdaq, Immortalised cell line, Metastasis, Mouse, Harvard Medical School, Coronavirus, Massachusetts Institute of Technology, GLOBE, Intellectual property, TTX, Technology, Annual report, CRISPR, Sirna, Radiology, Animal, Vaccine

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1 , in pancreatic adenocarcinoma.

Key Points: 
  • BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1 , in pancreatic adenocarcinoma.
  • This is the second drug candidate from TransCodes platform to show positive preclinical results in pancreatic cancer.
  • Pancreatic cancer has proven difficult to treat with conventional drugs and has been resistant to initial immunotherapy approaches.
  • TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics.

Nikon Instruments Inc. Opens Advanced Microscopy Center in San Francisco Bay Area

Retrieved on: 
Wednesday, February 9, 2022
Well, U.S.–Canada Team Tournament (go), TIRF, Artificial intelligence, Francisco B. Reyes Airport, Multimedia, FRAP, Nikon Instruments, SFO, FLIM, San Francisco Bay Area, Athinoula A. Martinos Center for Biomedical Imaging, STED, Organization, Center, STORM, SIM, NIS, PFS, Acquisition, Camera, Microscope, Nikon

MELVILLE, N.Y., Feb. 9, 2022 /PRNewswire/ -- Nikon Instruments Inc. today announced the opening of the Nikon Advanced Microscopy Center in the San Francisco Bay Area of Belmont, California.

Key Points: 
  • MELVILLE, N.Y., Feb. 9, 2022 /PRNewswire/ -- Nikon Instruments Inc. today announced the opening of the Nikon Advanced Microscopy Center in the San Francisco Bay Area of Belmont, California.
  • The Center features the latest Nikon Instruments product technologies and expands access to organizations in the West Coast region to test and evaluate these systems.
  • Well-versed in advanced imaging techniques and sample preparation, Nikon's experienced staff can address a diverse range of imaging needs.
  • Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications.

TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer

Retrieved on: 
Thursday, September 30, 2021
Oncology, Health, Other Health, Clinical Trials, Research, Science, Publication, Harvard Medical School, Neoplasm, Cancer, Breast, Lens, Biomedicine, Radiology, RNA, Recurrence, Security (finance), Therapy, Conference, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, MGH, TTX, Biology, Athinoula A. Martinos Center for Biomedical Imaging, CEO, Coronavirus, University, Company, Program, Sirna, Associate, Leadership, IOPC, Nanotechnology, Risk, Technology, COVID-19, PD-L1, Research, Glioblastoma, NIH, Drug discovery, Nanoparticle, Metastasis, Intellectual property, LIN28B (gene), Neuroimaging, Transcoding, Massachusetts General Hospital, Pharmaceutical industry, Management

TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced that Zdravka Medarova, Ph.D., has been appointed as the companys Chief Technology Officer effective October 1, 2021.

Key Points: 
  • TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced that Zdravka Medarova, Ph.D., has been appointed as the companys Chief Technology Officer effective October 1, 2021.
  • Dr. Medarova is a scientific co-founder of TransCode and has served as a member of TransCodes advisory board since its founding in January 2016.
  • We are delighted to welcome Zdravka as a full-time member of the TransCode team, said Michael Dudley, CEO of TransCode.
  • TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics.

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

Retrieved on: 
Thursday, September 23, 2021
Publishing, FDA, Genetics, Clinical Trials, Communications, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Food, Someren-Eind, Medical imaging, Harvard Medical School, Cancer, Breast, Neoplasm, PET, Pharmacokinetics, Observation, Radiology, RNA, Recurrence, Regulation of tobacco by the U.S. Food and Drug Administration, Security (finance), Therapy, Massachusetts, Private Securities Litigation Reform Act, Hospital, U.S. Securities and Exchange Commission, FDA, Patient, TTX, Athinoula A. Martinos Center for Biomedical Imaging, CEO, Coronavirus, Company, Risk, Technology, COVID-19, Human, IND, Research, Glioblastoma, Drug discovery, Nanoparticle, Intellectual property, Nasdaq, Transcoding, Department, Pharmaceutical industry

The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions.

Key Points: 
  • The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions.
  • These results suggest that TransCodes TTX platform delivers its therapeutic candidate as intended and the company believes supports clinical evaluation of TTX-MC138.
  • Our preclinical data further suggest the therapeutic potential of TTX-MC138, and we look forward to our Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.
  • The Companys lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide.